The global RNAi technology market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.8 billion in 2026 and USD 12.5 billion by 2035, representing a CAGR of 14.0% during the forecast period 2026 to 2035. RNA interference (RNAi) technology is a gene-silencing approach that selectively suppresses disease-causing genes at the messenger RNA (mRNA) level. Initially developed as a research tool, RNAi has evolved into a clinically validated therapeutic platform. Currently, the siRNA segment...

The global AI in clinical trials market, valued at USD 3.48 billion in 2025, is projected to reach USD 3.96 billion in 2026 and USD 11.61 billion by 2035, representing a CAGR of 12.7% during the forecast period 2026 to 2035. Based on the deployment mode, cloud-based AI solutions capture the largest share (around 75%) of the current market, and the trend is unlikely to change in the future. In terms of therapeutic areas, oncological disorders are expected to hold the largest market share (more th...

The global surgical robots market, valued at USD 9.8 billion in 2025, is projected to reach USD 10.6 billion in 2026 and USD 22.9 billion by 2035, with a 8.9% CAGR during the forecast period 2026 to 2035. In terms of geography, North America captures the majority of the market share.

The global next generation contact lenses and visual prostheses market, valued at USD 0.36 billion in 2024, is projected to reach USD 0.60 billion in 2025 and USD 16.97 billion by 2035, representing a CAGR of 39.7% during the forecast period. It is worth highlighting here that there is a rapid increase witnessed in the number of blind and partially sighted individuals. According to the National Eye Institute, nearly 1.3 million people are blind, while 2.9 million individuals have poor vision, in...

The global cell therapy manufacturing market, valued at USD 6.3 billion in 2025, is projected to reach USD 7.2 billion in 2026 and USD 14.0 billion by 2035, representing a CAGR of 7.7% during the forecast period 2026 to 2035. Researchers are investigating more than 1,000 cell and gene therapy candidates for the treatment of a myriad of disease indications. Amongst these, around 45 cell-based therapies have already been approved by various regulatory authorities across the globe. Further, several...

The global CAR-T cell therapy market, valued at USD 6.1 billion in 2025, is projected to reach USD 7.7 billion in 2026 and USD 15.6 billion by 2035, with a 8.1% CAGR during the forecast period 2026 to 2035. In terms of target antigen, the CD19 targeting therapies segment holds the highest share (more than 65%) of the market. With regards to target indication, the multiple myeloma segment dominates the global market with close to 30% market share. In terms of geographical regions, North America c...

The global Home Sleep Apnea Testing Market reached USD 1.90 billion in 2026 and is projected to reach USD 6.40 billion by 2040, growing at a CAGR of 9.1% over the forecast period 2026 to 2040, driven by untreated OSA prevalence, payer acceptance of HSAT, and AI-enabled multi-night diagnostics. Based on geography, North America captures 44.0% market share in 2026, whereas Asia-Pacific registers an 11.3% CAGR through 2040, driven by diagnostic-access gaps and local device innovation. Untreated obs...

The global hospital at home market reached USD 29.0 billion in 2026 and is projected to reach USD 199.1 billion by 2040, growing at a CAGR of 14.8% over the forecast period 2026 to 2040, driven by hospital capacity constraints. Based on geography, North America captures 46.0% market share in 2026, whereas Asia-Pacific registers a 17.3% CAGR through 2040, driven by virtual hospital scale-up. Based on component / offering, Services capture 54.0% market share in 2026, whereas Software platforms reg...

The small scale bioreactors market is estimated to grow from USD 2,479 million in 2025 to reach USD 2,739 million in 2026 and USD 5,796 million by 2035, representing a CAGR of 8.68% during the forecast period 2026 to 2035. In 2025, the batch / fed batch mode of operation dominated the market and is estimated to hold 90% of the overall revenue share by 2035. Fed batch bioreactors provide controlled nutrient environment, preventing accumulation of inhibitory byproducts that can limit cell growth....

The global mini bioreactors market, valued at USD 1.5 billion in 2025, is projected to reach USD 1.7 billion in 2026 and USD 4.0 billion by 2035, representing a CAGR of 10.4% during the forecast period 2026 to 2035. In terms of capacity of bioreactor, the 50 mL-250 mL segment holds the highest share of the current market. Based on the type of cell culture, the mammalian culture segment holds the largest share (close to 50%) of the current market.

The global contact lenses market, valued at USD 12.7 billion in 2025, is projected to reach USD 13.2 billion in 2026 and USD 20.5 billion by 2035, representing a CAGR of 5.0% during the forecast period 2026 to 2035. Contact lenses are thin, transparent optical devices placed directly on the cornea to correct refractive errors, and are currently worn by approximately 150 million individuals worldwide. In fact, in the US alone, an estimated 45 million people use contact lenses, with 87% opting fo...

The global big data in healthcare market, valued at USD 93 billion in 2025, is projected to reach USD 110 billion in 2026 and USD 540 billion by 2035, with a 19.37% CAGR during the forecast period 2026 to 2035. The geographical regions segment highlights the distribution of big data in healthcare market across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world regions. According to our projections, the big data analytic...

The ultrasound market is estimated to grow from USD 9.6 billion in 2025 to reach USD 10.2 billion in 2026 and USD 16.0 billion by 2035, representing a CAGR of 5.1% during the forecast period. In May 2026, ClearPoint Neuro entered into a collaboration with Sungkyunkwan University to expand its drug delivery ecosystem. The collaboration follows successful preclinical trials demonstrating ultrasound-enabled delivery across the blood-brain barrier, aiming to accelerate commercialization and global e...

The global Fc fusion protein market, valued at USD 40.7 billion in 2025, is projected to reach USD 45.0 billion in 2026 and USD 103.7 billion by 2035, representing a CAGR of 9.7% during the forecast period 2026 to 2035. In terms of type of fusion molecule, receptor ECD segment holds the highest share of the current market. In March 2026, Shanghai Henlius Biotech dosed the first patient in a Phase 1b/2 trial of HLX701, a next-generation SIRPα-Fc fusion protein, in combination with cetuximab and...

The global sexually transmitted disease (STD) testing market is expected to rise from USD 12.3 billion in 2026 to reach USD 33.0 billion by 2040, growing at a CAGR of 7.3% over the forecast period 2026 to 2040, driven by wider screening access and molecular-test adoption. Based on geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 9.4% CAGR through 2040, supported by expanding screening infrastructure.

The global nanoparticle formulation market, valued at USD 6.2 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 15.2 billion by 2035, with a CAGR of 9.3% during the forecast period 2026 to 2035. In June 2026, CEPI announced up to $9.7 million in additional funding to POP Biotechnologies to advance its SNAP nanoparticle-based vaccine platform into Phase 1 trials. The program targets rapid-response vaccines for epidemic threats such as H5N1 and Disease X, aiming to improve ant...

The global pulsed field ablation market, valued at USD 2.3 billion in 2025, is projected to reach USD 3.2 billion in 2026 and USD 14.6 billion by 2035, representing a CAGR of 18.4% during the forecast period 2026 to 2035. Clinical and preclinical research continues to expand the PFA evidence base, with multiple energy-delivery systems and procedural workflows under investigation. For instance, Boston Scientific’s FARAPULSE™ pulsed-field ablation (PFA) system demonstrated symptomatic relief i...

The E. coli fermentation market, valued at USD 7.8 billion in 2025, is projected to reach USD 8.6 billion in 2026 and USD 17.3 billion by 2035, representing a CAGR of 8.2% during the forecast period 2026 to 2035.Driven by the preference of major drug developers to retain end-to-end control over their proprietary microbial expression strains and quality control, the in-house manufacturers (~70%) dominate the E. coli fermentation market. In April 2026, WuXi Biologics achieved structural completion...

The mRNA vaccines market, valued at USD 12 million in 2025, is projected to reach USD 9 million in 2026 and USD 7,047 million by 2035 (this represents the market opportunityonly for mRNA vaccines developed for non-COVID applications). In terms of target indication, the respiratory syncytial virus (RSV) infection is likely to capture the majority of the current revenue share. In terms of geographical regions, North America accounts for the largest market share, primarily due to increased research...

The mRNA therapeutics market, valued at USD 201 million in 2027, is projected to reach USD 2,023 million by 2030 and USD 9,988 million by 2035 (this represents the opportunity only for those mRNA therapeutics that are developed for non-COVID applications). In terms of target indication, non-small cell lung cancer is anticipated to capture the majority of the revenue share by 2035. In terms of geographical regions, North America is expected to hold largest market share by 2035. In June 2026, BioN...